Frontlight ResearchEarly access
Not yet taking people in CzechiaPhase 3
Tests semaglutide effects on liver fat in adults with obesity and fatty liver
Tests semaglutide for 16 weeks in adults with obesity and fatty liver disease.
Key facts
- Who runs it
- Institut Klinicke A Experimentalni Mediciny
- Where
- Prague 4, CzechiaSee the site
- Trial code
- Registry title
- The effect of semaglutide therapy on hepatic fat content and on the acute response of liver fat to high-fat load
- Status
- Not yet recruiting
- Phase
- Phase 3
- People taking part
- 16 people, planned
- Started
- 1 Jan 2026
- Expected to end
- 31 Dec 2029
- Type of study
- Interventional
- Record updated
- 28 May 2025
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for men with obesity and fat in the liver. They would take semaglutide for 16 weeks.
- Age
- 18 to 70 years
- Sex
- Men only
- Disease stage
- BMI of 30 kg/m2 or more, waist circumference of 102 cm (3 ft 4 in) or more, and liver fat above 5,5 % on an MRS scan at screening
- Earlier treatment
- No weight loss drugs; no long-term corticosteroids or immunosuppressants; no weight change of more than 5 % in the 3 months before the trial
- Biomarker or test result
- Liver fat content above 5,5 % measured by MRS during screening
Main reasons for not taking part
- Type I or Type II diabetes
- Active cancer or a past liver transplant
- Alcohol use above 40 g/day
- Active hepatitis, liver cirrhosis, or pancreatitis
- Severe kidney failure or dialysis
The registry criteria, word for word
Show all 25 criteriaShow less
Who can take part
- sex: male
- age 18 – 70 years
- BMI ≥ 30 kg/m2
- waist circumference ≥102 cm
- hepatic fat content evaluated by MRS during screening > 5,5 %
Who cannot take part
- chronic treatment with corticosteroids or immunosuppressants
- significant change in weight (> 5 %) in the 3 months before the entering study
- acute myocardial infarction, unstable angina pectoris, stroke, pulmonary embolism during 3 months before the start of study
- diabetes mellitus Type I and Type II
- active malignancy
- history of liver transplantation or transplantation of insulin-producing tissue
- any other disease that, in the opinion of investigator, could endanger or disadvantage the patient if he were to participate in the clinical trial
- lactose intolerance, cow milk protein allergy or other intolerancies
- hypersensitivity to the active substance or to any auxiliary substance of investigational medicinal product
- heart failure NYHA IV
- active hepatitis, liver cirrhosis
- HbA1c ≥ 48 mmol/mol or fasting glycemia ≥ 7 mmol/l during screening
- triglyceride > 4 mmol/l during screening
- chronic renal insufficiency IV-V (eGFR ≤ 0,5 ml/s), end-stage renal failure, hemodialysis or peritoneal dialysis
- alcohol consumption > 40 g/day
- use of weight loss dugs
- lack of legal capacity
- refusal to sign informed consent
- untreated thyreopathy
- acute or chronic pancreatitis
Where in Czechia
- Institut Klinicke A Experimentalni MedicinyPrague 4, CzechiaNot yet recruiting
About the trial
What the trial wants to find out
- to determine whether the treatment with semaglutide for 16 weeks favorably affects hepatic fat volume - to determine whether the treatment with semaglutide for 16 weeks favorably affects the acute response of hepatic fat content to a high-fat load
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorData and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Official title
- The effect of semaglutide therapy on hepatic fat content and on the acute reponse of liver fat to high-fat load in obese MASLD patients
- Plain-language title
- Tests semaglutide effects on liver fat in adults with obesity and fatty liverGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 9 November 2026.
- Record updated
- 28 May 2025